Natco Pharma Limited has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The certificate, provided by Venture Capital and Corporate Investments Private Limited, confirms that securities received for dematerialization have been processed. This includes mutilation and cancellation of certificates after verification, and updating the depositories (NSDL and CDSL) as the registered owners within 15 days of receiving valid documentation. The company has furnished these details to the relevant stock exchanges.
